Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:...
News
TFF Pharmaceuticals Expands R&D Operations with New Austin Facility
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million...
TOWER ONE WIRELESS ANNOUNCES TWENTY-TWO TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $ 2,600,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF JUNE 2022VANCOUVER, BC, CANADA, July 14, 2022 (GLOBE NEWSWIRE) -- TOWER ONE...
OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland,...
SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022
BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today...
BUSINESS UPDATE
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals...
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths...
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2022 Financial Results on July 28, 2022
LEAMINGTON, Ontario, July 14, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY),...
BioAdaptives, Inc. Launching Next Generation Products for Natural Health Practitioners
Enhanced products For Use by Holistic Healthcare Practitioners – $21b US Market For Alternative Medicine Goods and Services LAS VEGAS,...
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Teleflex Announces Second Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second...
InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Continues its Growth, Adding 3 New US Contracts and a Significant New Sales Partnership
VANCOUVER, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
Healthcare Triangle Announces Closing of $6.5 Million Private Placement
PLEASANTON, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the “Company”), a leading provider...
Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide
STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a...